Taking puberty-blocking drugs has been shown to have negative effects on the mental health of transgender children, according to a recent analysis conducted by researchers at the University of Essex. The study re-examined the data from a previous study conducted in 2021 by NHS’s Gender Identity Development Service (GIDS) at Tavistock and University College London Hospitals (UCLH). This original study analyzed 44 children between the ages of 12 and 15 who were taking puberty blockers. The new analysis revealed that one-third of these transgender youth experienced a decline in mental health while on these drugs.
The specific drug in question is triptorelin, which is sold under the brand name Trelstar. Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that reduces certain hormone levels in the body. The original study claimed that the drugs had no impact on the mental health of the children over a 36-month follow-up period. However, the new analysis challenged this finding and found that 34% of the trans youth experienced a decline in mental health while taking the puberty blockers. In contrast, 37% reported no change in mental health, and 29% noticed an improvement.
To determine the extent of changes in mental health, the researchers analyzed emotional factors such as anxiety, depression, social withdrawal, and somatic complaints, as well as behavioral indicators like attention problems and aggressive behaviors. They also examined sleep difficulties. The new analysis took into account the individual psychological health of each child, revealing greater variation among them compared to the original study.
The researchers concluded that this analysis provides a more complete picture of the benefits and risks of treatment with puberty blockers. They recommend incorporating these findings into new gender dysphoria services in the U.K. and future research studies. However, it’s important to note that this analysis has not yet undergone peer review.
There are certain limitations to this study, including a small sample size and the absence of a control group. The available dataset for the children studied was also limited. While the results show an association between puberty blockers and mental health decline, they do not prove causation, as there may be other factors at play. It’s worth noting that hormones like testosterone, estrogen, and progesterone, which were suppressed by triptorelin, play a crucial role in mood regulation and cognition.
In conclusion, it is crucial to consider the potential risks and benefits of puberty-blocking drugs when treating transgender children. The impact of these drugs on mental health should be carefully evaluated, taking into account individual variations and potential adverse effects. Further research and analysis are needed to fully understand the implications of these findings.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
